Plain-English translation of NCT06496724 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new approach called Albumin-bound Paclitaxel combined with your own immune cells (called granulocytes or neutrophils) to treat breast cancer that has returned or spread. Doctors will collect some of your blood cells, grow them in a laboratory with the cancer medication, and then give the treatment back to you through an IV infusion. The goal is to see if this personalized approach can help fight your cancer more effectively.
Standard treatments for advanced breast cancer don't work for everyone, and some patients need new options. This trial explores whether combining a proven cancer drug with a patient's own immune cells might create a more powerful treatment that targets cancer cells while working with the body's natural defenses.
If you enroll, doctors will draw blood to collect your immune cells, which will be sent to a laboratory where they are grown and combined with the cancer medication over several days. Once ready, you will return to receive the treatment as an IV infusion into your bloodstream. You'll need to be healthy enough to undergo this process and will likely have follow-up visits to monitor how you respond to the treatment.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China